Literature DB >> 29523615

Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy.

Corey Toocheck1, Daniel Pinkhas1.   

Abstract

Cardiac extramedullary plasmacytomas (EMPs) are rare and may be a seen as a complication of multiple myeloma (MM) or in isolation. Here, we describe a case of cardiac EMP that presented clinically as a congestive heart failure exacerbation in a patient with relapsed and refractory IgG lambda MM. We highlight radiographic imaging in conjunction with laboratory biomarkers at presentation and in response to D-PACE (dexamethasone, cisplatin (Platinol), doxorubicin (Adriamycin), cyclophosphamide and etoposide) systemic chemotherapy. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  cancer - see oncology; chemotherapy; oncology

Mesh:

Substances:

Year:  2018        PMID: 29523615      PMCID: PMC5847829          DOI: 10.1136/bcr-2017-223611

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents.

Authors:  Anne-Marie Ronchetti; Françoise Isnard; Marc Buffet; Tereza Coman; Norbert-Claude Gorin; Paul Coppo; Laurent Garderet; Sandra Malak
Journal:  Leuk Lymphoma       Date:  2013-03-08

2.  Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts.

Authors:  C Alexiou; R J Kau; H Dietzfelbinger; M Kremer; J C Spiess; B Schratzenstaller; W Arnold
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

Review 3.  Extramedullary plasmacytoma of the heart presenting as cardiac emergency. Review of literature.

Authors:  Y K Keung; S Lau; P Gill
Journal:  Am J Clin Oncol       Date:  1994-10       Impact factor: 2.339

Review 4.  Extramedullary myeloma representing as a pericardial effusion with tamponade: two case reports and a further review of 19 cases in the literature.

Authors:  W Abelman; A Virchis; K Yong
Journal:  Leuk Lymphoma       Date:  2005-01

5.  D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.

Authors:  Alina S Gerrie; Joseph R Mikhael; Lu Cheng; Haiyan Jiang; Vishal Kukreti; Tony Panzarella; Donna Reece; Keith A Stewart; Young Trieu; Suzanne Trudel; Christine I Chen
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

Review 6.  Extramedullary Cardiac Multiple Myeloma-A Case Report and Contemporary Review of the Literature.

Authors:  Maria Coakley; Beeletsega Yeneneh; Allison Rosenthal; Rafael Fonseca; Farouk Mookadam
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-02-18
  6 in total
  3 in total

1.  2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway.

Authors:  FengChen Zhu; DianMing Jiang; MingHua Zhang; Bo Zhao
Journal:  Pharm Biol       Date:  2019-12       Impact factor: 3.503

Review 2.  Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies.

Authors:  Margaret E Stalker; Tomer M Mark
Journal:  Curr Oncol       Date:  2022-06-23       Impact factor: 3.109

3.  Myeloma Spine and Bone Damage Score (MSBDS) on Whole-Body Computed Tomography (WBCT): Multiple Reader Agreement in a Multicenter Reliability Study.

Authors:  Alberto Stefano Tagliafico; Clarissa Valle; Pietro Andrea Bonaffini; Ali Attieh; Matteo Bauckneht; Liliana Belgioia; Bianca Bignotti; Nicole Brunetti; Alessandro Bonsignore; Enrico Capaccio; Sara De Giorgis; Alessandro Garlaschi; Silvia Morbelli; Federica Rossi; Lorenzo Torri; Simone Caprioli; Simona Tosto; Michele Cea; Alida Dominietto
Journal:  Diagnostics (Basel)       Date:  2022-08-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.